HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis, Body Composition
Conditions
Brief summary
Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.
Interventions
DIAGNOSTIC_TESTWhole body MRI
Whole body MRI will be performed as part of a study protocol
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
University of California, San Francisco
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.
Exclusion criteria
* Women who are not virally suppressed (HIV RNA \>200 copies/mL) * Women who are not on antiretroviral therapy * Women who have a history of hysterectomy or oophorectomy * Women who are receiving treatment for active cancer or tuberculosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Markers of immune activation and inflammation | These markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point. | sCD14 (monocyte activation), sCD163 (M2 macrophage activation), CRP (inflammation), IL-6 (inflammation), IP-10 (interferon-inducible protein), TNFα (inflammation), MCP-1 (inflammation), sTNFRI & RII (inflammation). There are no units as they will be normalized based upon their interquartile range. |
Countries
United States
Contacts
Primary ContactRebecca A Abelman, MD
Backup ContactStacy Polos
Outcome results
None listed